Target intelligence / Profile preview

Mitochondrial nicotinamide adenine dinucleotide transporter SLC25A51 (SLC25A51)

Target
SLC25A51
Molecular classification
Transporter, Solute carrier family, Mitochondrial carrier family (SLC25)
01

Overview

Mitochondrial nicotinamide adenine dinucleotide transporter SLC25A51 (SLC25A51) is a member of the mitochondrial carrier (solute carrier family 25) responsible for importing NAD+ into the mitochondrial matrix, a process vital for maintaining mitochondrial respiration and cellular energy production[1][2][3]. Loss of SLC25A51 leads to depletion of mitochondrial NAD+, impaired respiration, and disruption of bioenergetic homeostasis, while overexpression restores mitochondrial function[1][3]. SLC25A51 is conserved across eukaryotes and is the functional ortholog of yeast NDT1, essential for ensuring sufficient NAD+ for metabolic pathways including the TCA cycle and electron transport chain[2][3][4]. Molecular studies reveal a transport mechanism involving specific lipid interactions and a ligand-induced gating process controlling NAD+ import[4]. No therapeutically approved drugs are currently known to target SLC25A51 directly, but its essential role in mitochondrial metabolism positions it as a candidate target for studying mitochondrial function and metabolic disease intervention[1][2][3].

Other names
MCART1Mitochondrial carrier triple repeat protein 1SLC25A51MGC14836CG7943mitochondrial NAD+ transportermitochondrial NAD(+) transporter SLC25A51mitochondrial carrier triple repeat 1mitochondrial nicotinamide adenine dinucleotide transporter SLC25A51mitochondrial NAD+ transporter SLC25A51
02

Mechanism of action

NAD+ transport across the inner mitochondrial membrane

03

Biological functions

Mitochondrial NAD+ importRegulation of cellular respirationMaintenance of mitochondrial redox homeostasisBioenergetics/metabolic support
04

Disease associations

Other (impairment leads to mitochondrial dysfunction and may be involved in energy metabolism disorders; precise disease links are under investigation)
05

Safety considerations

Complete loss is lethal or causes severe bioenergetic defects in cells[1][3]Therapeutic targeting could disrupt cellular energy metabolism[3]

Beyond the preview

Go deeper on Mitochondrial nicotinamide adenine dinucleotide transporter SLC25A51 (SLC25A51).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial nicotinamide adenine dinucleotide transporter SLC25A51 (SLC25A51).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call